Traditional methods to commercially produce therapeutic proteins include purification from plasma and expression of recombinant proteins in nonhuman producer cells. Unfortunately there are limitations to both of these approaches that lead to a market shortage of therapeutic proteins. The global supply of human plasma is limited and there will always be the risk of unknown viral contamination. On the other hand posttranslational modification of complex recombinant proteins derived from animal cells is "less than perfect" and thus may result in less functional proteins that require higher dosing that can lead to tolerance and rejection. MultiCell's immortalized human hepatocyte BioFactories™ continue to secrete a spectrum of proteins including clotting factors and alpha-1-antitrypsin that are virtually indistinguishable from plasma derived proteins. The Company is seeking strategic partners to co-develop genetically engineered producer cells that secrete correctly processed proteins in mass culture.